Although hepatocellular carcinoma (HCC) has become a common indication for liver transplantation (LT), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) are historically contraindicated due to their aggressive behavior. On the basis of recent experiences, some groups have proposed a clinical trial investigating the role of LT for patients with early cholangiocarcinoma (CCA), defined as a single lesion £ 2 cm. The purpose of this study is to assess the clinicopathologic features and outcomes following LT for patients who were initially diagnosed with HCC and subsequently found to have either ICC or cHCC-CCA on explant. Patients with the diagnosis of primary liver cancer (PLC) after LT from a single center were retrospectively reviewed. Outcomes for patients with early CCA were compared with patients with HCC within Milan criteria (MC). Out of 618 patients transplanted with PLC, 44 patients were found to have CCA on explant. On the basis of preoperative imaging, 12 patients met criteria for early CCA and were compared with 319 patients who had HCC within MC. The 1-and 5-year overall survival for early CCA versus HCC was 63.6% versus 90.0% and 63.6% versus 70.3% (log-rank, P 5 0.25), respectively. Overall recurrence was 33.3% for early CCA versus 11% for HCC. On explant the patients with CCA were more likely understaged with higher tumor grade and vascular invasion. In conclusion, patients with CCA present a diagnostic challenge, which often leads to the finding of more aggressive lesions on explant after LT, higher recurrence rates, and worse post-LT survival. Careful consideration of this diagnostic conundrum needs to be made before a clinical trial is undertaken.
Liver transplantation (LT) offers a surgical option for patients with primary liver cancers (PLCs) that renders the widest possible surgical margin as well as addresses the predominant risk factor for cancer by replacing the cirrhotic liver. (1, 2) Patients with hepatocellular carcinoma (HCC) have seen the greatest proven benefit with 3-year survival as high as 80% in carefully selected patients as defined by the Milan criteria (MC). (3) (4) (5) (6) Intrahepatic cholangiocarcinoma (ICC) is the second most common PLC (approximately 10% of all hepatobiliary malignancy). (7) Even with aggressive treatment and resection, 5-year survival for patients with ICC remains approximately 24%. (8, 9) Because of the high risk for recurrence and poor longterm outcomes, ICC is typically a contraindication for LT. (10, 11) Biphenotypic tumors (combined hepatocellular carcinoma-cholangiocarcinoma [cHCC-CCA]) are the rarest type of PLCs (<1% of all liver cancers) (12) and have a natural history which is least understood. Reliant on small series of unintentionally transplanted patients with cHCC-CCA, longterm outcomes have yielded mixed results with 5-year posttransplant survival ranging between 8% and 86%. (13) (14) (15) (16) (17) The poor outcomes for these patients are due in large part to the ICC component of these tumors, which recur after LT at a higher rate.
Despite this controversy, several groups have proposed that LT may provide acceptable longterm survival in carefully selected patients with ICC as defined by small unifocal disease without vascular invasion and low pathologic grade. (18) (19) (20) From a large multicenter retrospective study, Sapisochin et al. found that patients with early ICC on explant have outcomes similar to patients with HCC within MC. (19) They defined early ICC as a single lesion 2 cm found on explant pathology. From these results, the authors have proposed a prospective trial to possibly offer LT to patients who otherwise have limited options. In order to implement such a trial, however, 2 primary challenges exist:
1. Our understanding of both ICC and cHCC-CCA in the setting of LT remains limited due to the paucity of large uniform clinical experiences. 2. The diagnostic challenge of accurately characterizing early ICC or cHCC-CC before LT. (21, 22) Even with distinct radiologic patterns, ICC continues to be misdiagnosed and unintentionally transplanted among roughly 1%-3% of all LT. (20, 23) Herein we present a single-center experience of 618 consecutive patients transplanted with the pre-LT diagnosis of HCC. Of these patients, 44 were misdiagnosed radiographically and found on explant to have either ICC or cHCC-CCA. In this retrospective review, we compare outcomes for patients who would meet criteria for early cholangiocarcinoma (CCA) versus patients with HCC within MC. A secondary analysis was performed to identify risk factors for recurrence.
Patients and Methods

COHORT SELECTION
Following institutional review board approval, a retrospective review of all charts from patients undergoing LT for HCC at Mayo Clinic Florida from February 1998 to February 2016 was performed. Data on preand post-LT variables were manually extracted from the patients' records. Patients with incidental tumors detected only on pathologic examination were also included initially. Pre-LT imaging modalities relied largely on intravenous (IV) contrast-enhanced magnetic resonance imaging (MRI) and/or IV contrast-enhanced computed tomography (CT). Although standard MRI with gadolinium IV contrast was the center's preferred modality for tumor follow-up, EOVIST (gadoexetate disodium) enhanced MRI was performed rarely for difficult to characterize lesions. CT scans with IV contrast was used only if MRI was contraindicated. Pre-LT locoregional treatments (LRTs) were performed in most patients, unless contraindicated. LRT included transarterial chemoembolization (TACE), transarterial radioembolization (TARE), percutaneous ethanol injection, and/or radiofrequency ablation (RFA). Histopathologic information regarding the size, number, type, grade, pattern, percentage of tumor necrosis, and location of tumor was collected. Macrovascular invasion (LVI) and microvascular invasion (SVI) invasion were reported. Tumor staging was performed in accordance with the United Network for Organ Sharing (UNOS) staging classification. (24) Understaging was defined as explant pathology that was a higher T stage according to UNOS classification when compared with preoperative imaging. The pathologic diagnosis of all ICC or cHCC-CCA tumors was reconfirmed by an expert hepatopathologist. All recurrence biopsies from patients with either ICC or cHCC-CCA were reviewed.
Patients in each group were classified according to posttransplant and pretransplant classifications. Posttransplant classifications included the following: early CCA pathology, which included patients with a single ICC or cHCC-CCA tumor 2 cm on explant without vascular invasion; advanced CCA pathology, which included patients with a single ICC or cHCC-CCA tumor >2 cm or multifocal tumors of any size or with vascular invasion (patients with combined ICC or cHCC-CCA with HCC were included in this group because they had multifocal tumors); HCC T1 pathology, which included patients with either complete response to LRT or had single lesions 2 cm on explant; HCC T2 pathology, which included patients with lesions meeting MC (a single lesion 5 cm, or no greater than 3 lesions with none of them >3 cm); and advanced HCC pathology, which included patients with lesions beyond MC.
Pretransplant classifications included early CCA patients who had radiologically small tumors (a single tumor 2 cm) and were misdiagnosed as HCC but later found to be ICC or cHCC-CCA on explant. HCC within MC included patients with pathologic diagnosis of HCC on explant and initial radiographic lesions meeting MC. All tumors that were incidentally found and radiographically occult were excluded from either the CCA or HCC groups.
Post-LT recurrence is defined by any recurrence during the follow-up period after LT. Monitoring involved serum alpha-fetoprotein (AFP) measurements, along with bone scans and cross-sectional imaging at 4, 8, 12, 24 , and 36 months after LT. Carbohydrate antigen 19-9 was not monitored regularly in any protocol and not included in the data set. Standard clinical follow-up occurred at 4, 8, and 12 months, and then annually thereafter.
DATA ANALYSIS
All numeric data were reported as mean, median, and range. Comparison between groups was performed using the chi-square test for categorical variables. Student t test was applied for parametric continuous variables. The natural log of nonparametric continuous variables was used to adjust for nonnormal distribution. P < 0.05 was considered significant.
Survival time started with the day of LT. Overall survivals in each group were estimated using the Kaplan-Meier method, and groups were compared using the log-rank test. Nelson-Aalen cumulative hazard models were applied to estimate risk of recurrence over time. Potential risk for recurrence was investigated using logistic regression models. These relationships were illustrated as odds ratio (OR) and 95% confidence interval (CI). Multivariate models were selected using a backward stepwise selection technique with a retention P value of <0.1. Statistical analysis was performed using STATA, version 13 (StataCorp, College Station, TX). A statistical significance was assigned at P value < 0.05.
Results
During this study period, 2932 patients underwent primary LT; 618 (21.1%) patients were diagnosed with PLC of which 44 (1.5%) were misdiagnosed and later found to have ICC or cHCC-CCA on explant and 574 had HCC. There was no era effect on the incidence of misdiagnosing either ICC or cHCC-CCA, and these lesions consistently represented 1-3 patients transplanted each year during the study period. Mean follow-up was 4.2 years. Of these 44 patients, 9 had a single lesion of ICC on explant. Eight patients had a combination of ICC with HCC tumors on explant (Goodman type 1). (25) Sixteen patients had cHCC-CCA lesions on explant (Goodman type 2). One patient had a combination of cHCC-CCA lesions with a single foci of ICC. Ten patients had a combination of cHCC-CCA lesions with HCC lesions. Recurrence for either ICC or cHCC-CCA ranged from 29.4% to 40.7%. The 1-and 5-year overall survival ranged from 76.9% to 81.3% and from 55.0% to 64.5%, respectively. Demographic and clinicopathologic data are presented in Table 1 . The only statistically significant difference between patients with ICC and cHCC-CCA was in regards to the number of tumors seen on preoperative imaging. However, there was no difference on final pathologic number. As well, patients with cHCC-CCA had a statistically higher percentage of SVI (P 5 0.04). Out of 16 patients with either ICC or cHCC-CCA who had recurrence, 13 recurrence biopsies were reviewed; 12 (92%) of these were CCA. Only when biopsy confirmed the recurrence tumor type were the data included in Table 1 . Because of the minimal differences in outcome and clinicopathologic features between ICC and cHCC-CCA in this cohort, we decided to treat them as 1 common entity-as patients with CCA.
RADIOGRAPHIC APPEARANCE
The preoperative imaging for the misdiagnosed CCA lesions were rereviewed by our liver radiologist, and we found that many of the CCA lesions had atypical features for HCC. Although 100% of the lesions had arterial enhancement, only 72% had washout, and 55% demonstrated progressive enhancement. When compared with a sampling of pathology-confirmed HCC lesions, 98% had arterial enhancement with 81% showing washout and 6.4% having progressive enhancement.
EXPLANT PATHOLOGY REVIEW: COMPARISON OF CCA VERSUS HCC
Of the 44 patients with CCA, 16 patients met criteria for early CCA as previously described (early CCA path) compared with 28 who had advanced CCA. Of the 574 patients who had HCC, 85 (14.8%) had a complete response to LRT compared with 0 among the patients with CCA; 225 (39.2%) patients had HCC that showed near complete response, with a single lesion 2 cm or multiple lesions none 1 cm; 161 (28.0%) patients had HCC within MC on explant and 
OUTCOME: COMPARISON OF CCA VERSUS HCC
Overall recurrence for patients with CCA was 36.4% versus 10.8% for patients with HCC (P < 0.001). The 1-and 5-year overall survival for CCA versus HCC was 78.6% versus 91.0% and 54.5% versus 71.5%, respectively. Figure 1A demonstrates the KaplanMeier survival for the pathologic categories of early CCA pathology versus advanced CCA pathology versus HCC T1 pathology versus HCC T2 pathology versus advanced HCC path (HCC beyond MC). There was a statistically significant difference in survival for either early CCA pathology or advanced CCA pathology when compared with HCC T1 (P 5 0.03 or P < 0.01, respectively). However, there was no statistical difference when comparing either of these 2 groups with HCC T2 pathology (P 5 0.23 and 0.14, respectively). The only other statistically significant difference between the groups was when comparing the advanced HCC pathology to either the HCC T1 pathology or HCC T2 pathology (P < 0.001 for both). Figure 1B demonstrates the cumulative risk of recurrence as modeled for patients with early CCA pathology versus advanced CCA pathology versus HCC T1 pathology versus HCC T2 pathology versus the advanced HCC pathology. With respect to recurrence, patients with early CCA pathology and advanced CCA pathology both had statistically significant increased risk for recurrence when compared with either HCC T1 pathology or HCC T2 pathology. Overall recurrence for early CCA pathology was 29.4% and for advanced CCA pathology was 40.7%. This was statistically significantly worse than for HCC T1 pathology (3.6%) and HCC T2 pathology (11.2%) and comparable to advanced HCC pathology (38.7%).
COMPARISON OF EARLY CCA VERSUS HCC WITHIN MC BASED ON PRE-LT IMAGING
Patients were then divided according to preclinical factors. Twelve patients had radiographically small lesions that were misdiagnosed as HCC and found to have early CCA-these lesions would have met criteria for the proposed clinical trial (ie, only had 1 tumor that was 2.0 cm). There were 319 patients who met initial radiologic criteria for HCC within MC. Table 2 summarizes the clinicopathologic features of these 2 groups. Among the pretransplant variables, there were no statistically significant differences between the 
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groups. As would be expected in the comparison of these 2 groups, there is a statistically significant difference in the size and number of tumors for those HCCs within MC and the early CCA groups. In the early CCA group, we found that 66.7% were understaged (according to UNOS classification) as compared with 11.5% of the patients with HCC. They also had more SVI and higher-grade tumors. Recurrence was statistically higher for patients with early CCA versus HCC within MC (33.3% versus 11%; P 5 0.02). The 1-and 5-year survival rates were inferior for early CCA versus HCC within MC (63.6% versus 90.0% and 63.6% versus 70.3%), but they were not statistically significant (log-rank, P 5 0.25). Figure 2A showed Kaplan-Meier modeled survival for early CCA versus HCC within MC, which was not statistically NOTE: Data are given as mean 6 standard deviation (median; range) and n (%). ICC and cHCC-CCA were compared using Student t test for normally distributed continuous variables and Wilcoxon-Mann-Whitney U test for nonparametric continuous variables.
For categorical values, chi-square testing was performed. P < 0.05 was considered significant. *ln AFP (max) is the natural log of the peak pretransplant AFP level. † Cause of death: percentage represented as percentage of patients who died.
significant (P 5 0.25). Figure 2B shows the cumulative risk for recurrence between early CCA versus HCC within MC (P 5 0.01). Table 3 demonstrates the factors associated with tumor recurrence for all patients with PLC. Univariate analysis demonstrated that the following variables were correlated with an increased risk for recurrence: pathologic diagnosis of CCA on explant, vascular invasion, radiologically being outside of MC on imaging, having a tumor outside MC on explant, not having a complete response to LRT on explant, and increasing AFP maximum. On multivariate analysis, having CCA on explant was independently associated with risk for recurrence. Other variables included vascular invasion, pathology that was beyond MC, and higher AFP maximum before LT. Table 3 also demonstrates the univariate analysis for risk factors associated with recurrence among the CCA patients alone. Table 3 also demonstrates the subanalysis performed on CCA patients alone. Univariate analysis was performed on all the previously identified risk factors (including vascular invasion, tumor size, tumor grade, and In AFP) for recurrence including a comparison of whether the pathology demonstrated ICC or cHCC-CCA. None of these variables were able to predict post-LT recurrence.
RISK FOR RECURRENCE
Discussion
In this manuscript, we present our experience with 44 patients who were misdiagnosed before LT and found to have ICC or cHCC-CCA on explant. Similar to previously described reports, the frequency of misdiagnosis and unintentional LT for patients found to have ICC or cHCC-CCA was 1.5%. Overall outcomes for these patients were significantly worse in both overall survival and risk for recurrence as compared with patients who were found to have HCC. Survival for patients with early CCA pathology and advanced CCA pathology was not statistically significantly worse than patients with HCC T2 pathology. However, there was a trend to inferior survival. The 1-and 5-year survival rates for patients with early CCA pathology versus advanced CCA pathology versus HCC T2 pathology were 87.7% versus 74.1% versus 91.4% and 35.6% versus 61.4% versus 70%, respectively. This inferior survival was in large part due to the higher recurrence rate among patients of early CCA pathology (29%) and advanced CCA pathology (40.7%) as compared with patients with HCC T1 pathology (3.6%) or T2 pathology (11.2%).
Despite this increased risk for recurrence, the role of LT for CCA remains attractive because it still provides the best longterm survival over any other therapy. As a result of recent favorable reports, the role of LT for CCA has been gaining enough momentum to encourage a clinical trial. Identifying the right patients for whom acceptable results are possible becomes the challenge. Up until now, all prior analyses that attempted to identify favorable patient selection (ie, early CCA) 
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depended on pathologic data, which would be unknown until after LT. To simulate a proposed clinical trial investigating LT for early CCA, we sought to compare outcomes for patients with radiologically identified early tumors that were later found to be CCA. Outcomes for these patients were compared with patients with HCC within MC based on imaging prior to LT. Although most preclinical variables were not different, after review of the explant, patients who had early CCA on imaging were understaged more frequently, less likely to have a complete response to LRT, and more likely to have vascular invasion and unfavorable tumor grade. These variables all were found to be critical variables for predicting recurrence in our multivariate model. In this way, these results provide caution to the growing interest in developing a prospective trial to treat CCA patients with early disease. Several conclusions can be derived from this experience. First, these data affirm the perception that ICC or cHCC-CCA is very difficult to diagnose radiologically. Just as in every major study, all 44 of these patients were misdiagnosed as either having HCC or no tumor at all. Even in a study of large tumors (average size 5 7.7 cm), sensitivity for cHCC-CCA was estimated to be 34%. (22) The diagnosis for small ICC can be equally as challenging, as Huang et al. noted that the classic enhancement patterns for ICC become less reliable with lesions 2 cm. (26) Even after confirming the diagnosis with pathology, our findings highlight these radiographic challenges in attempting to distinguish between CCA and HCC. Although, in retrospect, there was an increased preponderance of progressive enhancement seen in the lesions which had CCA components, this was seen in only 55% of these lesions, and even some HCC lesions had the same features. These challenges become all the more magnified in the real clinical setting where hundreds of lesions are seen weekly. As the community proposes to move forward with a prospective trial, we would encourage a review of many of these misdiagnosed lesions from a large and varied experience to standardize our imaging protocols as well as diagnostic criteria-perhaps even the more widely used pre-LT biopsy of liver lesions. Second, if an atypical tumor is seen on preoperative imaging, there is a significant risk or probability that this tumor will be understaged, as seen by a 66.7% understaging rate in our experience. Unfortunately, even with a more widespread use of pre-LT biopsy, staging or even tumor grading of these lesions may continue to be underestimated. Sampling error may also contribute to misdiagnosis, especially in the setting of mixed tumors, where the HCC component may be more prominent and the CCA component is missed. Third, patients regardless of whether they are early or advanced CCA based on preoperative imaging have an estimated recurrence of at least 30%. (23, (27) (28) (29) Even in the international multicenter cohort that suggested early CCA as candidates for LT, they reported a recurrence rate of 13%-20% in the early group. (19) In today's climate with the critical organ shortage and disparate mortality for patients with cancer Model for EndStage Liver Disease (MELD) exception points versus patients with cirrhosis with equal natural MELD scores, such a high recurrence rate may be unacceptable. (30) Fourth, patients with ICC or cHCC-CCA are typically unresponsive to LRT with a high percentage of these patients with viable CCA on explant. This finding was not unique to our experience but has been shared by several groups, which report only a quarter of patients have a partial or even complete response to TACE or TARE. (31) (32) (33) With RFA, there have been some reports with local control of the tumors. However, nearly all patients in this study eventually had progression of their disease, suggesting at best a partial response to treatment. (34) Moving forward, the role of LRT needs to be further investigated, especially in the setting of a future trial with LT; drawing from the hilar CCA experience, this may be the best approach to providing LT with curative intent. (35, 36) Until we understand how to identify the best LRT as well as the most responsive tumor candidates, it would be challenging to propose a clinical trial that continues to generate inferior outcomes for the scarce resource of LT. Fifth, recurrence for patients with CCA was very difficult to predict in our model. This failure to identify predictive factors may be due to the small overall number of patients (with only 16/44 recurring). However, moving forward, these factors will need to be better understood. Perhaps a multicenter registry of all misdiagnosed patients who underwent transplantation could be reviewed to address this question with enough power to understand this. Sixth, when patients with ICC or cHCC-CCA recur, they almost always recur with ICC-as demonstrated by 92% of our recurrence biopsies showing CC-highlighting the possibility that CCA even with small lesions may behave differently than HCC. This challenge adds to the complexity for post-LT surveillance and management of recurrence because CCA presents both diagnostic and therapeutic challenges.
Recently, UNOS policy has been adjusted to reduce expedited priority for LT in the setting of patients with HCC. By lengthening the wait time for these patients, the transplant community has created an opportunity to observe the biology of these suspicious lesions. Aggressive tumors, such as CCA, may declare themselves sooner by progression, and hopefully, fewer misdiagnosed lesions will go to LT. As suggested by our data set, and yet not statistically significant, patients who were misdiagnosed tended to have a shorter waiting time. At the same time, waiting longer may identify patients who have more favorable CCA and may benefit from LT. The impact of wait time will need to be further investigated on LT outcomes as this new policy is implemented.
Although the strength of this manuscript includes the largest reported single-center series with detailed longterm follow-up and a uniform practice, there remain several weaknesses inherent to retrospective studies. Like all previously published reports regarding ICC or cHCC-CCA treated by LT, our series is challenged by an overall small number of patients and perhaps is underpowered to clearly demonstrate statistically significant differences in overall survival. This highlights the importance of future multicenter collaborations to prospectively address the utility and benefit of LT for patients with such a rare tumor as CCA. (18) In regards to the finding that no CCA patient had a complete response, it is possible that among the 85 patients who showed no viable tumor on explant after LRT some of these patients may have had CCA that has been rendered completely necrotic. We found, however, that among the patients with CCA who underwent LRT, the average percentage of necrosis was 7.6% as opposed to 75.1% for the patients with HCC-supporting the claim that CCA is likely not responsive to LRT.
Patients with either isolated ICC or cHCC-CCA were combined for analysis in this study for several reasons. First, due to the limited experience of misdiagnosing and transplanting patients with either ICC or cHCC-CCA, finding a large enough experience to achieve statistical significance in a single uniform practice would be improbable until such a clinical trial is designed. Second, radiographically, cHCC-CCA is even more difficult to identify than HCC or ICC. (37) If a clinical trial were to begin, thereby loosening the inclusion criteria of PLCs for LT, the number of cHCC-CCA misdiagnosed and transplanted is likely to increase. Third, in our experience, the radiographic challenge of misdiagnosis as well as clinical presentation, and even posttransplant recurrence and survival rates, were similar between ICC and cHCC-CCA-so that we felt meaningful conclusions could be drawn from the collective experience if they were treated as 1 diagnostic challenge. Fourth, many of those authors who advocate for a clinical trial have excluded cHCC-CCA because they have previously demonstrated "that the results of LT in patients diagnosed with mixed HCC-CCA at explant were more than acceptable (5-year survival 78%)." (19) For this reason, we felt that cHCC-CCA would be fair to include in this analysis especially when our analysis still demonstrated inferiority of outcomes for patients with misdiagnosed ICC as compared with those with HCC.
In summary, this study reports outcomes for 44 patients who were discovered to have ICC or cHCC-CCA on explant. When we examined patients with early ICC or cHCC-CCA as seen on pre-LT imaging, we found that the size, number, tumor grade, and degree of vascular invasion were all greatly understaged and that these patients resulted in a high recurrence rate. Until our pre-LT imaging or diagnostic capabilities improve, caveat emptor for patients with CCA.
